PNCA1
MCID: PNC094
MIFTS: 27

Pancreatic Cancer 1 (PNCA1) malady

Categories: Genetic diseases, Endocrine diseases, Cancer diseases, Rare diseases, Gastrointestinal diseases

Aliases & Classifications for Pancreatic Cancer 1

Aliases & Descriptions for Pancreatic Cancer 1:

Name: Pancreatic Cancer 1 54 66 29
Pancreatic Cancer, Susceptibility to, 1 13
Pnca1 66

Classifications:



External Ids:

OMIM 54 606856
MedGen 40 C1847351
MeSH 42 D010190

Summaries for Pancreatic Cancer 1

UniProtKB/Swiss-Prot : 66 Pancreatic cancer 1: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

MalaCards based summary : Pancreatic Cancer 1, also known as pancreatic cancer, susceptibility to, 1, is related to pancreatic cancer and pancreatic cancer susceptibility 1. An important gene associated with Pancreatic Cancer 1 is PALLD (Palladin, Cytoskeletal Associated Protein). The drugs Secretin and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include pancreas.

Description from OMIM: 606856

Related Diseases for Pancreatic Cancer 1

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 2
Pancreatic Cancer 3 Pancreatic Cancer 4

Diseases related to Pancreatic Cancer 1 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 pancreatic cancer 10.9
2 pancreatic cancer susceptibility 1 10.8

Symptoms & Phenotypes for Pancreatic Cancer 1

Clinical features from OMIM:

606856

Drugs & Therapeutics for Pancreatic Cancer 1

Drugs for Pancreatic Cancer 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 620)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Secretin Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 108153-74-8
2
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
3
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
5
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 1 128794-94-5 5281078
6
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1 24280-93-1 446541
7
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
8
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
9
Tacrolimus Approved, Investigational Phase 4,Phase 1,Phase 2 104987-11-3 445643 439492
10
Daclizumab Approved, Investigational Phase 4,Phase 1,Phase 2 152923-56-3
11
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
12
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 33069-62-4 36314
13
Etanercept Approved, Investigational Phase 4,Phase 1,Phase 2 185243-69-0
14
Metformin Approved Phase 4,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
15
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
16
Somatostatin Approved Phase 4,Phase 3,Phase 1,Phase 2 38916-34-6, 51110-01-1 53481605
17
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2 9041-08-1
18
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 9005-49-6 772 46507594
19
Etomidate Approved Phase 4 33125-97-2 36339 667484
20
Meperidine Approved Phase 4 57-42-1 4058
21
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
22
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
23
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
24
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 2078-54-8 4943
25
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
26
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
27
Nicotine Approved Phase 4 54-11-5 942 89594
28
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
29
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
30
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
31
Diphenhydramine Approved Phase 4,Phase 2,Phase 1 58-73-1, 147-24-0 3100
32
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-23-7 5754 657311
33
Promethazine Approved Phase 4,Phase 2,Phase 1 60-87-7 4927
34
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1 108736-35-2
35
Morphine Approved, Investigational Phase 4 57-27-2 5288826
36
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
37
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
38
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
39 Tegafur Approved Phase 4,Phase 2,Phase 1 17902-23-7
40
alemtuzumab Approved, Investigational Phase 4,Phase 2,Phase 3 216503-57-0
41 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
42 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
43 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
47 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
48 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Antilymphocyte Serum Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 1669)
id Name Status NCT ID Phase
1 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
2 Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis Unknown status NCT01845467 Phase 4
3 A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids Unknown status NCT00693446 Phase 4
4 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
5 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4
6 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4
7 Prospective Study of Celiac Block Injection: 1 vs. 2 Completed NCT00583479 Phase 4
8 Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Completed NCT00966277 Phase 4
9 Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer Completed NCT01346410 Phase 4
10 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
11 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4
12 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
13 Effects of Dexmedetomidine During IRE Procedures for Solid Tumours Completed NCT02044224 Phase 4
14 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4
15 The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery Completed NCT02728921 Phase 4
16 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
17 Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy Completed NCT02757690 Phase 4
18 A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients Completed NCT00363116 Phase 4
19 Spy II Clinical Registry Completed NCT00751998 Phase 4
20 Long-Term Lamivudine Therapy for Chronic Hepatitis B Completed NCT00120354 Phase 4
21 Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study Recruiting NCT01768988 Phase 4
22 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Recruiting NCT02812992 Phase 4
23 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
24 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
25 Anti-inflammatory Therapy to Improve Outcomes After TPIAT Recruiting NCT02713997 Phase 4
26 Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Recruiting NCT02500147 Phase 4
27 A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer Active, not recruiting NCT02237157 Phase 4
28 Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy Active, not recruiting NCT02238847 Phase 4
29 Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation Active, not recruiting NCT00331162 Phase 4
30 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Active, not recruiting NCT03083210 Phase 4
31 Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial Tumors Enrolling by invitation NCT02884154 Phase 4
32 Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer Not yet recruiting NCT02945267 Phase 4
33 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Not yet recruiting NCT02570529 Phase 4
34 Comparison Study in Pancreatic Fiducial Placement Not yet recruiting NCT02376543 Phase 4
35 Quality of Life After BDA or Stents to Treat Biliary Obstruction in Pancreas Cancer Terminated NCT01887041 Phase 4
36 A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer Terminated NCT00642733 Phase 4
37 A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer Unknown status NCT01586611 Phase 3
38 Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer Unknown status NCT00813696 Phase 3
39 Hyperthermia European Adjuvant Trial Unknown status NCT01077427 Phase 3
40 Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III) Unknown status NCT01065870 Phase 2, Phase 3
41 A Phase 3 Study to Compare Efficacy and Safety of Masitinib in Combination With Gemcitabine, to Placebo in Combination With Gemcitabine, in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer Unknown status NCT00789633 Phase 3
42 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
43 Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer Unknown status NCT00268411 Phase 3
44 Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine Unknown status NCT00440167 Phase 3
45 Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer Unknown status NCT00486460 Phase 3
46 Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas Unknown status NCT02311439 Phase 2, Phase 3
47 Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery Unknown status NCT01655641 Phase 2, Phase 3
48 The ARTERY FIRST Approach for Resection of Pancreatic Head Cancer Unknown status NCT01332773 Phase 3
49 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
50 Effectiveness of Microwave Ablation of Hepatocellular Carcinoma as Compared to Radiofrequency Ablation Unknown status NCT01340105 Phase 3

Search NIH Clinical Center for Pancreatic Cancer 1

Genetic Tests for Pancreatic Cancer 1

Genetic tests related to Pancreatic Cancer 1:

id Genetic test Affiliating Genes
1 Pancreatic Cancer 1 29

Anatomical Context for Pancreatic Cancer 1

MalaCards organs/tissues related to Pancreatic Cancer 1:

39
Pancreas

Publications for Pancreatic Cancer 1

Variations for Pancreatic Cancer 1

ClinVar genetic disease variations for Pancreatic Cancer 1:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PALLD NM_001166110.1(PALLD): c.415C> T (p.Pro139Ser) single nucleotide variant risk factor rs121908291 GRCh37 Chromosome 4, 169799457: 169799457

Expression for Pancreatic Cancer 1

Search GEO for disease gene expression data for Pancreatic Cancer 1.

Pathways for Pancreatic Cancer 1

GO Terms for Pancreatic Cancer 1

Sources for Pancreatic Cancer 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....